mkdir -p /home/daytona/workspace/anki-cards && cat > /home/daytona/workspace/anki-cards/hemostasis_anki.txt << 'ANKI_EOF' Hemostasis - Mechanism, Coagulation Cascade, Tests, Osler-Weber-Rendu <b>HEMOSTASIS - OVERVIEW</b><br><br>Hemostasis is a precisely orchestrated process involving platelets, clotting factors, and endothelium that forms a blood clot at sites of vascular injury to prevent or limit bleeding. Steps: (1) Vasoconstriction - immediate neurogenic reflex, mediated by endothelin. (2) Primary hemostasis - platelet plug formation. (3) Secondary hemostasis - fibrin deposition via coagulation cascade. (4) Clot stabilization - factor XIII crosslinks fibrin, platelet contraction.<br><br><b>PRIMARY HEMOSTASIS - PLATELET PLUG FORMATION</b><br><br>Vascular injury exposes subendothelial collagen and vWF. Platelet adhesion: GpIb receptor on platelet binds vWF (bridge to collagen). Deficiency of vWF = von Willebrand disease. Deficiency of GpIb = Bernard-Soulier syndrome (large platelets, prolonged BT, normal PT, normal PTT, abnormal ristocetin test). Platelet activation: shape change (disc to sea-urchin), secretion of granules - alpha-granules release fibrinogen, factor V, vWF, PDGF, P-selectin. Dense (delta) granules release ADP, ATP, calcium, serotonin, epinephrine. ADP and TXA2 recruit more platelets. Aspirin inhibits COX, blocks TXA2, causes mild bleeding. Platelet aggregation: fibrinogen bridges GpIIb-IIIa receptors. Deficiency of GpIIb-IIIa = Glanzmann thrombasthenia (normal platelet count, prolonged BT, absent aggregation, normal ristocetin test).<br><br><b>SECONDARY HEMOSTASIS - COAGULATION CASCADE</b><br><br>Intrinsic pathway (PTT measures): XII (Hageman) - XI - IX - VIII - X. Activated by contact with negatively charged surfaces. Extrinsic pathway (PT measures): Tissue factor (TF) + VII - X. TF exposed by subendothelial cells (smooth muscle, fibroblasts). Common pathway: X + V (prothrombinase complex) - II (prothrombin) - IIa (thrombin) - cleaves fibrinogen to fibrin - XIII crosslinks fibrin. Factors requiring Vitamin K (gamma-carboxylation): II, VII, IX, X, Protein C, Protein S. Calcium essential - binds gamma-carboxylated residues. Thrombin is the KEY factor: converts fibrinogen to fibrin, activates XIII, V, VIII, XI (feedback amplification), activates platelets via PAR-1, is procoagulant at injury site but anticoagulant on intact endothelium via thrombomodulin.<br><br><b>REGULATION OF COAGULATION - ANTICOAGULANT MECHANISMS</b><br><br>Endothelium releases: PGI2 (prostacyclin) and NO - inhibit platelet aggregation. Adenosine diphosphatase - degrades ADP. Thrombomodulin binds thrombin - activates Protein C (with Protein S as cofactor) - inactivates factors Va and VIIIa. Antithrombin III - inactivates thrombin, IXa, Xa, XIa, XIIa (enhanced by heparin). TFPI (tissue factor pathway inhibitor) - inhibits TF-VIIa complex. Fibrinolysis: Plasminogen activated to plasmin by t-PA (from endothelium) or urokinase. Plasmin degrades fibrin. D-dimers are fibrin degradation products - marker of thrombosis. Alpha-2 antiplasmin inhibits free plasmin.<br><br><b>TESTS FOR HEMOSTASIS</b><br><br>Bleeding Time (BT): Normal 2-8 min (some sources up to 8-10 min borderline). Tests platelet function and vascular integrity. Prolonged in: thrombocytopenia, vWD, Bernard-Soulier, Glanzmann thrombasthenia, aspirin use. Platelet Function Analyzer (PFA-100) has replaced BT in many labs - more sensitive for vWD and drug-induced platelet dysfunction. PT (Prothrombin Time): Normal 11-13 sec (INR 0.8-1.2). Tests extrinsic and common pathway (VII, X, V, II, fibrinogen). Prolonged in: factor VII deficiency (isolated PT prolongation), warfarin use, liver disease, vitamin K deficiency, DIC. INR therapeutic range: 2-3 (most indications), 2.5-3.5 (mechanical heart valves). aPTT (Activated Partial Thromboplastin Time): Normal 25-35 sec. Tests intrinsic and common pathway (XII, XI, IX, VIII, X, V, II, fibrinogen - all except VII and XIII). Activated by kaolin or glass (negatively charged). Prolonged in: hemophilia A (VIII deficiency), hemophilia B (IX deficiency), factor XII deficiency (no bleeding), heparin therapy, lupus anticoagulant, DIC. Thrombin Time (TT): Tests fibrinogen - fibrin conversion. Prolonged by heparin, dysfibrinogenemia, low fibrinogen. Platelet Count: Normal 150,000-400,000/mm3. Thrombocytopenia less than 100,000/mm3. Spontaneous bleeding risk below 20,000/mm3. Fibrinogen level and D-dimer: Useful in DIC. D-dimer elevated in DVT, PE, DIC. Clot solubility test: Factor XIII deficiency (clot dissolves in urea). Ristocetin cofactor assay: Tests vWF function.<br><br><b>KEY PATTERN RECOGNITION FOR NEET PG</b><br><br>Prolonged BT only - platelet disorder or vascular defect. Prolonged aPTT only - intrinsic pathway defect (hemophilia A, B, factor XII def). Prolonged PT only - factor VII deficiency, early warfarin effect. Prolonged PT and aPTT - common pathway defect, liver disease, DIC, severe vitamin K deficiency. Normal PT and aPTT with bleeding - factor XIII deficiency, platelet disorder, vWD. Bernard-Soulier: prolonged BT, large platelets, deficient GpIb, abnormal ristocetin. Glanzmann thrombasthenia: prolonged BT, normal count, deficient GpIIb-IIIa, absent aggregation, normal ristocetin. Hemophilia A: isolated aPTT prolonged, factor VIII deficiency, X-linked recessive. Hemophilia B: isolated aPTT prolonged, factor IX deficiency, X-linked recessive.<br><br><b>OSLER-WEBER-RENDU SYNDROME (Hereditary Hemorrhagic Telangiectasia - HHT)</b><br><br>Autosomal dominant. Frequency ~1 in 5000. Mutations in ENG gene (endoglin, chromosome 9) or ACVRL1 gene (ALK1, chromosome 12) - both encoding TGF-beta receptor components. Pathology: structurally abnormal vascular walls (telangiectasias and AVMs). Coagulation tests ALL NORMAL (primary vascular defect, not platelet or coagulation defect). Clinical features by age: Childhood - recurrent epistaxis (first and most common symptom). Adolescence to young adulthood - skin telangiectasias on face, lips, ears, chest, oral mucosa. Fourth to fifth decade - GI bleeding from telangiectasias or AVMs. AVMs can also occur in brain, lung, and liver. Diagnosis: Curacao criteria (epistaxis, telangiectasias, visceral AVMs, family history - 3 of 4 = definite). BT may be prolonged (vascular defect), PT and aPTT normal. Treatment: Iron supplementation, laser photocoagulation, antifibrinolytic agents, bevacizumab for refractory cases. ANKI_EOF echo "Exit code: $?"

wc -l /home/daytona/workspace/anki-cards/hemostasis_anki.txt && echo "---" && grep -c $'\t' /home/daytona/workspace/anki-cards/hemostasis_anki.txt && echo "tabs found" && python3 -c " with open('/home/daytona/workspace/anki-cards/hemostasis_anki.txt','r') as f: content = f.read() lines = content.split('\n') print(f'Total lines (split on newline): {len(lines)}') print(f'Non-empty lines: {sum(1 for l in lines if l.strip())}') parts = content.strip().split('\t') print(f'Tab-separated parts: {len(parts)}') # Check for pipes or semicolons in actual content print(f'Pipes: {content.count(chr(124))}') print(f'Semicolons: {content.count(chr(59))}') print(f'Actual newlines in file: {content.count(chr(10))}') "